Subcutaneous administration of amifostine: a promising therapeutic option in patients with oxaliplatin-related peripheral sensitive neuropathy.
Penz
M
M
Kornek
G V
GV
Raderer
M
M
Ulrich-Pur
H
H
Fiebiger
W
W
Scheithauer
W
W
D000328:Adult; D000368:Aged; D004999:Amifostine / Q000008:administration & dosage*; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010865:Pilot Projects; D011837:Radiation-Protective Agents / Q000008:administration & dosage*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011837:Radiation-Protective Agents; D000077150:Oxaliplatin; D004999:Amifostine